B cell and aquaporin‐4 antibody relationships with neuromyelitis optica spectrum disorder activity
Year: 2024
Type: article
Abstract: This post hoc analysis of the randomized, placebo‐controlled N‐MOmentum study (NCT02200770) of inebilizumab in neuromyelitis optica spectrum disorder (NMOSD) evaluated relationships between circulating B‐cell subsets and aquaporin‐4 immunoglobulin G (AQP4‐lgG) titers and attacks. Among participants receiving placebo, CD20 + and CD27 + B‐cell counts were modestly increased from the pre‐attack visit to attack; plasmablast/plasma cell gene signature was increased from baseline to the pre‐attack visit ( p = 0.016) and from baseline to attack ( p = 0.009). With inebilizumab treatment, B‐cell subset counts decreased and did not increase with attacks. No difference in change of AQP4‐IgG titers from baseline to time of attack was observed.
DOI: 10.1002/acn3.52171
Institutions: University of Colorado Anschutz, Mayo Clinic, Max Delbrück Center, Charité - Universitätsmedizin Berlin, National Cancer Center, National Cancer Center Hospital, University of Oxford, Mayo Clinic in Florida, Yale University, Amgen (United States), University of California, San Francisco
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,990
Funders: Amgen, AstraZeneca, Sanofi, Biogen, Teva Pharmaceutical Industries, Alexion Pharmaceuticals, Guthy-Jackson Charitable Foundation, CSL Behring, Handok, Wellcome Trust, TG Therapeutics, Atara Biotherapeutics, Argenx, Horizon Therapeutics, National Institute for Health and Care Research, National Research Foundation, Deutsche Forschungsgemeinschaft, National Research Foundation of Korea, Eisai, Daewoong Pharmaceutical Company, Astellas Pharma, Mitsubishi Tanabe Pharma Corporation, Genentech, EMD Serono, Sanofi Genzyme, Medical Research Council
OpenAlex ID: W4402125573